Addyi
Rather than a failed “fix-all” pill, NWHN encourages rigorous research be conducted exploring the causes of women’s sexual problems, possible solutions, and what, if anything, might constitute “normal” when it comes to women’s sexuality.
FOR IMMEDIATE RELEASE
Contact: Nora Brodnitz at nora@wcsemail.com or 202-471-0043
FOR IMMEDIATE RELEASE
To schedule an interview with Cindy Pearson contact: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994
The NWHN is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido.
FOR IMMEDIATE RELEASE
To schedule an interview with Cindy Pearson and Susan Wood, contact Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994
The National Women’s Health Network is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido. Rather than rely on drug company marketing, NWHN recommends that women educate themselves and pass on the pink pill.
FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640
Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
I’m disappointed and you should be too. Today, the Food & Drug Administration announced the approval of flibanserin, a proposed treatment for “hypoactive sexual desire disorder” in women. Since its founding, the National Women’s Health Network has ensured that the voices of women consumers are heard and respected. Today, clever marketing trumped decades worth of consumer protections that the Network has worked hard to secure and maintain.
- « Previous
- 1
- 2
- 3
- Next »